Archive Newsletter
-
05.02.24 -- Inside BlueRock Therapeutics' Parkinson's Disease Trial
5/2/2024
05/02/24 Cell & Gene Newsletter
-
05.01.24 -- Learn How To Reduce Translational Failure Through Next Generation Organ-on-a-Chip Technology
5/1/2024
05/01/24 Cell & Gene Newsletter
-
05.01.24 -- Developing A Process Performance Qualification Master Plan
5/1/2024
05/01/24 Cell & Gene Newsletter
-
04.30.24 -- Achieve Peak Performance: Optimize Your Bioprocessing Workflow
4/30/2024
04/30/24 Cell & Gene Newsletter
-
04.30.24 -- 2024: The Year Of Development In Cell Therapy
4/30/2024
04/30/24 Cell & Gene Newsletter
-
04.29.24 -- Leverage The FDA's Expedited Programs To Address Genetically-Driven Diseases
4/29/2024
04/29/24 Cell & Gene Newsletter
-
04.29.24 -- What Time Is Best To Bring My CDMO On Board?
4/29/2024
04/29/24 Cell & Gene Newsletter
-
04.25.24 -- Insights From Across The Globe: Trends In Clinical Trials
4/25/2024
04/25/24 Cell & Gene Newsletter
-
04.25.24 -- Reducing The Disease Burden Of AML With Vor Bio's Dr. Robert Ang
4/25/2024
04/25/24 Cell & Gene Newsletter
-
04.24.24 -- Outsourcing Best Practices To Increase Efficiency And Compliance
4/24/2024
04/24/24 Cell & Gene Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more